RhumbLine Advisers
KLRS

RhumbLine Advisers’s Kalaris Therapeutics KLRS Stock Holding History

RhumbLine Advisers’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-804
Closed -$13.4K – 4355
2024
Q2 		$13.4K Sell
804
-2,196
-73% -$38.8K ﹤0.01% 3936
2024
Q1 		$52.1K Buy
3,000
+234
+8% +$3.82K ﹤0.01% 3617
2023
Q4 		$43.3K Sell
2,766
-693
-20% -$27.3K ﹤0.01% 3660
2023
Q3 		$171K Buy
3,459
+682
+25% +$46.5K ﹤0.01% 3243
2023
Q2 		$217K Buy
2,777
+673
+32% +$64K ﹤0.01% 3201
2023
Q1 		$191K Sell
2,104
-53
-2% -$6.75K ﹤0.01% 2748
2022
Q4 		$254K Buy
2,157
+83
+4% +$14.1K ﹤0.01% 2727
2022
Q3 		$376K Buy
2,074
+186
+10% +$29K ﹤0.01% 2626
2022
Q2 		$169K Buy
1,888
+640
+51% +$67.1K ﹤0.01% 2971
2022
Q1 		$194K Buy
1,248
+44
+4% +$8.78K ﹤0.01% 2764
2021
Q4 		$358K Sell
1,204
-22
-2% -$10.2K ﹤0.01% 2646
2021
Q3 		$707K Buy
1,226
+57
+5% +$26.4K ﹤0.01% 2392
2021
Q2 		$531K Sell
1,169
-86
-7% -$44.4K ﹤0.01% 2538
2021
Q1 		$675K Buy
1,255
+390
+45% +$328K ﹤0.01% 2358
2020
Q4 		$765K Buy
865
+167
+24% +$128K ﹤0.01% 2261
2020
Q3 		$441K Buy
+698
New +$477K ﹤0.01% 2343

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RhumbLine Advisers's KLRS Position: Q3 2024 in Review

RhumbLine Advisers sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 804 shares — an estimated $13.4K sold.

RhumbLine Advisers first reported a position in KLRS in Q3 2020 and held it in 16 quarters. The position peaked at $765K in Q4 2020. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • RhumbLine Advisers reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 804 Kalaris Therapeutics shares in Q3 2024, an estimated $13.4K.
  • RhumbLine Advisers first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 16 quarters.
  • RhumbLine Advisers's Kalaris Therapeutics position peaked at $765K in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.